Loading...
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Oza, A Cook, A Pfisterer, J Embleton, A Ledermann, J Pujade-Lauraine, E Kristensen, G Carey, M Beale, P Cervantes, A
Oza, A
Cook, A
Pfisterer, J
Embleton, A
Ledermann, J
Pujade-Lauraine, E
Kristensen, G
Carey, M
Beale, P
Cervantes, A
Citations
Altmetric:
Abstract
The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the greatest effect in patients at high risk of disease progression. We report the final overall survival results of the trial.
Description
Date
2015-06-23
Publisher
Collections
Keywords
Type
Article
Citation
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. 2015: Lancet Oncol